Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia

Ilaria Schiavetto, Paolo Pedrazzoli, Vera Basilico, Salvatore Siena

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis- stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue.

Original languageEnglish
Pages (from-to)417-420
Number of pages4
JournalChemotherapy
Volume54
Issue number6
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Hematinics
Anemia
Iron
Neoplasms
Drug Therapy
Therapeutics
Chronic Renal Insufficiency
Clinical Trials

Keywords

  • Cancer-related anemia
  • Erythropoiesis-stimulating agents
  • Iron supplementation

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery

Cite this

Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia. / Schiavetto, Ilaria; Pedrazzoli, Paolo; Basilico, Vera; Siena, Salvatore.

In: Chemotherapy, Vol. 54, No. 6, 10.2008, p. 417-420.

Research output: Contribution to journalArticle

Schiavetto, Ilaria ; Pedrazzoli, Paolo ; Basilico, Vera ; Siena, Salvatore. / Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia. In: Chemotherapy. 2008 ; Vol. 54, No. 6. pp. 417-420.
@article{32a88e2170cc447b80d493b749fb6859,
title = "Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia",
abstract = "Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis- stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue.",
keywords = "Cancer-related anemia, Erythropoiesis-stimulating agents, Iron supplementation",
author = "Ilaria Schiavetto and Paolo Pedrazzoli and Vera Basilico and Salvatore Siena",
year = "2008",
month = "10",
doi = "10.1159/000158539",
language = "English",
volume = "54",
pages = "417--420",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Iron supplementation during treatment with erythropoiesis-stimulating agents for cancer-related anemia

AU - Schiavetto, Ilaria

AU - Pedrazzoli, Paolo

AU - Basilico, Vera

AU - Siena, Salvatore

PY - 2008/10

Y1 - 2008/10

N2 - Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis- stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue.

AB - Unresponsiveness to erythropoiesis-stimulating agents is a major limitation to the treatment of chemotherapy-related anemia. This is often related to a disregulation of iron metabolism leading to functional iron deficiency. However, the use of iron supplementation during treatment with erythropoiesis- stimulating agents has not been as rigorously pursued in anemic patients with cancer as it has in chronic kidney disease. In this article, we review and discuss the role of iron supplementation in the setting of chemotherapy-related anemia in view of recently published clinical trials addressing this issue.

KW - Cancer-related anemia

KW - Erythropoiesis-stimulating agents

KW - Iron supplementation

UR - http://www.scopus.com/inward/record.url?scp=52549109865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52549109865&partnerID=8YFLogxK

U2 - 10.1159/000158539

DO - 10.1159/000158539

M3 - Article

VL - 54

SP - 417

EP - 420

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 6

ER -